- Conditions
- Obesity
- Interventions
- eloralintide and tirzepatide, Eloralintide, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 55
- States / cities
- Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more
Condition Directory
Type 2 Diabetes clinical trials
Directory of U.S. ClinicalTrials.gov public records for Type 2 Diabetes. Browse Type 2 Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 22, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3771
Shown on this page
12
Current sort
Recently updated
Condition scope
Type 2 Diabetes
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Type 2 Diabetes studies are organized in the registry
Type 2 diabetes records also appear under generic “diabetes” and the abbreviation T2DM, so checking both phrasings gives fuller coverage. The portfolio spans drug trials, lifestyle programs, and large cardiovascular-outcome studies; the study-type filter separates the observational cohorts from interventional trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 25–36 of 3,771 matching trials for Type 2 Diabetes.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Type 2 Diabetes
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Orforglipron, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 17
- States / cities
- Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,023 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 54
- States / cities
- Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
- Conditions
- Type 2 Diabetes Mellitus, T2DM
- Interventions
- HM15275, Placebo of HM15275
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Santa Clarita, California • DeLand, Florida + 14 more
- Conditions
- Diabete Type 2, Obesity & Overweight, Nutritional Intervention, Food Insecurity
- Interventions
- Meal kits, No-prep meals, Culinary nutrition classes, Text messages
- Behavioral
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV, Hypertension, Hypercholerolemia, Type 2 Diabetes
- Interventions
- Preventative health review invitation early in SNAP cycle, Financial counseling invitation early in the SNAP cycle, Aim 3 follow-up call early in the SNAP period, Preventative health review invitation late in SNAP cycle, Financial counseling invitation late in the SNAP cycle, Aim 3 follow-up call late in the SNAP cycle
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity, Obesity (Body Mass Index >30 kg/m2)
- Interventions
- Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation
- Device · Procedure
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- Liraglutide Pen Injector, Saline Injections
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Interventions
- Semaglutide, Zenagamtide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
- Interventions
- Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
About this Type 2 Diabetes clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Type 2 Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Type 2 Diabetes.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Type 2 Diabetes.